These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 16215959)

  • 41. Back to the future: driving innovation in drug development.
    Wagner JA
    Clin Pharmacol Ther; 2008 Feb; 83(2):199-202. PubMed ID: 18202681
    [No Abstract]   [Full Text] [Related]  

  • 42. Therapeutic peptides revisited.
    Latham PW
    Nat Biotechnol; 1999 Aug; 17(8):755-7. PubMed ID: 10429238
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Quality specifications for peptide drugs: a regulatory-pharmaceutical approach.
    Vergote V; Burvenich C; Van de Wiele C; De Spiegeleer B
    J Pept Sci; 2009 Nov; 15(11):697-710. PubMed ID: 19750489
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
    Manning M; Stoev S; Chini B; Durroux T; Mouillac B; Guillon G
    Prog Brain Res; 2008; 170():473-512. PubMed ID: 18655903
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Economics of new oncology drug development.
    DiMasi JA; Grabowski HG
    J Clin Oncol; 2007 Jan; 25(2):209-16. PubMed ID: 17210942
    [TBL] [Abstract][Full Text] [Related]  

  • 46. How do pharmaceutical companies approach data from sexual health studies for regulatory agencies?
    Dilleen M; Haughie S
    Annu Rev Sex Res; 2005; 16():53-61. PubMed ID: 16913287
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The cyclotides and related macrocyclic peptides as scaffolds in drug design.
    Craik DJ; Cemazar M; Daly NL
    Curr Opin Drug Discov Devel; 2006 Mar; 9(2):251-60. PubMed ID: 16566295
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluating solutions to sponsorship bias.
    Doucet M; Sismondo S
    J Med Ethics; 2008 Aug; 34(8):627-30. PubMed ID: 18667655
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Promises of biomarkers in drug development--a reality check.
    Marrer E; Dieterle F
    Chem Biol Drug Des; 2007 Jun; 69(6):381-94. PubMed ID: 17581232
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Challenges in natural health product research: The importance of standardization.
    Shan JJ; Rodgers K; Lai CT; Sutherland SK
    Proc West Pharmacol Soc; 2007; 50():24-30. PubMed ID: 18605225
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Drug development for children: how is pharma tackling an unmet need?
    Hawcutt DB; Smyth RL
    IDrugs; 2008 Jul; 11(7):502-7. PubMed ID: 18600597
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The synthesis of naturally occurring peptides and their analogs.
    Cupido T; Tulla-Puche J; Spengler J; Albericio F
    Curr Opin Drug Discov Devel; 2007 Nov; 10(6):768-83. PubMed ID: 17987528
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Handing over the baton: connecting medicinal chemistry with process R&D.
    Federsel HJ
    Drug News Perspect; 2008 May; 21(4):193-9. PubMed ID: 18560618
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Looking forward in pharmaceutical process chemistry.
    Davies IW; Welch CJ
    Science; 2009 Aug; 325(5941):701-4. PubMed ID: 19661417
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Partnership between small biotech and big pharma.
    Wiederrecht GJ; Hill RG; Beer MS
    IDrugs; 2006 Aug; 9(8):560-4. PubMed ID: 16871465
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Globalization of quantitative pharmacology: first international symposium of quantitative pharmacology in drug development and regulation.
    Barrett JS; Shi J; Xie HT; Huang XH; Fossler MJ; Sun RY
    J Clin Pharmacol; 2008 Jul; 48(7):787-92. PubMed ID: 18490494
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The rise of the generic drug market and its implications for dermatology.
    Bhosle M; Balkrishnan R; Dewan T; Yelverton CB; Feldman SR
    J Dermatolog Treat; 2005; 16(5-6):295-8. PubMed ID: 16428148
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Serum stability of peptides.
    Jenssen H; Aspmo SI
    Methods Mol Biol; 2008; 494():177-86. PubMed ID: 18726574
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Peptide therapeutics: current status and future directions.
    Fosgerau K; Hoffmann T
    Drug Discov Today; 2015 Jan; 20(1):122-8. PubMed ID: 25450771
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Building parity between brand and generic peptide products: Regulatory and scientific considerations for quality of synthetic peptides.
    Wu LC; Chen F; Lee SL; Raw A; Yu LX
    Int J Pharm; 2017 Feb; 518(1-2):320-334. PubMed ID: 28027918
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.